Editas Medicine Q3 2026 Results: Net Loss of $23.4M, Loss Narrows
Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.
- Key figure
- Net loss $23.4M